Shares of Alnylam Pharmaceuticals, Inc. (ALNY) were down 8.5% on Aug. 30, after the company announced detailed data from the phase III HELIOS-B, which evaluated its investigational RNAi therapeutic, Amvuttra (vutrisiran) for an expanded indication.The HELIOS-B study is seeking to expand the label of Amvuttra for the treatment of transthyretin-mediated (ATTR) amyloidosis with cardiomyopathy.Per the company, the HELIOS-B study met the primary endpoint, demonstrating a statistically significant reduction in th ...